熱門資訊> 正文
ARS Pharmaceuticals任命新CEO
2026-07-08 04:35
- ARS Pharmaceuticals (SPRY) appointed Donn Casale as chief executive officer and director, effective July 7, 2026, succeeding co-founder Richard Lowenthal.
- Richard Lowenthal stepped down as an employee and officer of the company, effective July 6, 2026.
- Casale previously served as president of ARS Pharmaceuticals and brings more than 25 years of biopharmaceutical commercial leadership experience.
More on ARS Pharmaceuticals
- ARS Pharma: Strong Growth Meets A Coverage Wall
- ARS Pharmaceuticals: Still A Buy As Neffy Access Improves
- ARS Pharmaceuticals, Inc. (SPRY) Q1 2026 Earnings Call Transcript
- Biggest stock movers Thursday: AI chip stocks, WEN, HTZ, and more
- ARS Pharmaceuticals plunges 23% as neffy fails to secure insurance coverage
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
